Selected abstract submissions will be presented during Oral Abstract Sessions generally lasting for 2 hours. Authors will present their peer-reviewed research in a specific topic area, and presentations will be moderated by experts in the field. A Scientific Overview may be included in an Oral Abstract Session, as appropriate, or a moderator may provide a brief translational summary at the close of a session. Comoderators will introduce speakers and facilitate audience questions.
Oral presenters will be allocated 10 minutes for their presentation and 5 minutes for questions and answers with the audience. If the presentation exceeds 10 minutes, the moderator will shorten the Q&A period that follows the presentation.
Presentations from randomized trials and cohorts should follow the International Committee of Medical Journal Editors (ICMJE) guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. See the ICMJE guidelines for more details.
Appropriate information and correct terminology should be used with regard to sex and gender. For human clinical or epidemiological studies, sex-stratified results should be provided or who was included if it includes only a single population. Appropriate terminology such as cisgender (people whose gender match the sex assigned at birth) or transgender (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in the presentation.
Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.”
Please also note whether the study is ongoing or completed and whether the results are preliminary or final.
A title slide with the presenter’s financial disclosures (based on the information submitted with the abstract) will be provided when the presenter uploads their final slides in the speaker ready room at CROI. Disclosure information includes all financial relationships with commercial entities (eg, pharmaceutical and diagnostic companies) as submitted by the presenter. If there are no financial relationships to report, the disclosure will read “Nothing to Disclose.” Below is an example of a title slide that will be provided at CROI.
Our experience indicates that up to 10 slides is optimal, allowing 1 minute per slide. Presenters may choose to use more than 10 slides but should be sure to complete the presentation within the allocated 10 minutes. The content slides should give an overview of the research with conclusions and future research direction.
Please note that corporate logos, QR codes, and bar codes are not permitted on slides for oral presentations at CROI.
CROI will support only MS PowerPoint or Apple Keynote. Please ensure that all presentations are in one of these supported formats. High definition (HD) projectors will be used for all CROI sessions. Please apply widescreen formatting when preparing slides (aspect ratio 16:9; resolution 1920 x 1080).
Speakers must bring their slides on a portable drive to the Speaker Ready Room so slides can be uploaded to the presentation computer. All presenters should bring their slides to the Speaker Ready Room at least 24 hours in advance of their presentation.
If study data are accepted for publication or presentation after the abstract submission to CROI, and that publication or presentation is expected to take place before CROI, the presenting author must contact CROI at CROIabstracts@iasusa.org to provide details as soon as the presentation is accepted for review, presentation, or publication in another venue or outlet. Please be aware that, although publication in these circumstances will not necessarily prevent presentation of the research at CROI, our strong preference is that any additional publication or presentation happen either simultaneous to or following presentation at CROI. Requests to publish or present research accepted for presentation at CROI prior to its presentation at CROI will be evaluated on a case-by-case basis. Failure to notify the conference promptly regarding plans to publish or present a CROI-accepted abstract prior to CROI may result in the removal of the study from the conference program.